This week’s biotechnology news headlines include, Gates Foundation grant for low cost polio vaccine, Sanofi and Amgen close to getting support for cholesterol medicines in UK by offering discounts, CRISPR drug maker Intellia raises $108 million, Medicare Part B prescription pilot program, Daiichi buys Japanese rights to UK heart stem Cell Therapy, Federal microbiome project moving forward, and Intarcia moves toward diabetes treatment approval.
Cell Culture Events
Webinars:
Bioprocess Insights Webinar Series:
Unlocking the Potential for Efficiency in Downstream Bioprocesses
Wed, May 18, 2016 – Time:11:00 AM EDT – Duration:30 minutes
Madhu Raghunathan will walk you through several innovative strategies for achieving increased efficiency in buffer handling, chromatography unit operations, and downstream processing in general.
Register Now.
Single-Use Technology and Sustainability: Quantifying the Environmental Impact
Wed, June 1, 2016 – Time:11:00 AM EDT – Duration:30 minutes
Bill Flanagan will talk about sustainability and how this relates to single-use technologies in biomanufacturing operations. He will present new data on the implications of a single-use strategy from a sustainability perspective.
Register Now.
BIO International Convention – June 6-9, 2016 – San Francisco, CA
http://convention.bio.org/Cell Line Development & Engineering – June 13-15, 2016 – Parc 55 Wyndham San Francisco, CA
http://www.ibclifesciences.com/CellLine/overview.xml
Co-located with
Bioconjugates: From Targets to Therapeutics – http://www.ibclifesciences.com/Bioconjugates/overview.xmlNext Generation Protein Therapeutics Summit – http://www.ibclifesciences.com/ProteinSummit/overview.xmlAnnual Meeting of the International Society for Stem Cell Research – June 22-25, 2016, San Francisco, CA
http://www.isscr.org/home/annual-meeting/san-francisco-2016Progress in Continuous Biomanufacturing – June 27-28, 2016 – Robinson College, Cambridge, UK
The conference is enhanced by the participation of several leading industrial technologists, scientific, vendors and also leading academics from Europe and USA. They have come forward to share their experience and knowledge to provide a better understanding of the current technologies and their application in continuous biomanufacturing. There is also a plenary lecture by a distinguished professor in the field of bioprocessing, and you will also benefit from access to unpublished data. This meeting will address several advancements and their successful application with data in the Technology both Upstream and downstream and also on Initiatives to process developments and project to the future direction of the industry. By joining with us you can benefit from the current state of-the-art advancements in continuous manufacturing and also learn about the successful organisations that are developing and applying these methods in-house.
http://www.subramanian.org.uk/Viral Safety and Raw Materials – June 2016, Vienna, Austria
http://www.informa-ls.com/event/empoweredantibodies15
“The latest biopharmaceutical company testing Wall Street’s belief in the promise of gene modification has gone public. Intellia Therapeutics (NASDAQ: NTLA) of Cambridge, MA, which owns rights to an important but disputed piece of the CRISPR-Cas9 gene editing technology, sold 6 million shares at $18 each this evening to raise $108 million. Its stock will trade on the Nasdaq starting tomorrow under the ticker “NTLA.”
If you like this story, please see our blog titled “The CRISPR/Cas9 System and its Applications”
“The May 2 editorial “Drug money,” which endorsed the Obama administration’s proposed Medicare Part B pilot program, did a serious disservice to the patients whose health would be jeopardized by this misguided experiment.
If you like this story, please see our blog titled “2015 FDA New Drug Approvals – 13 Biologics Receive Approval”
“A Welsh stem cell company founded by a Nobel prize winner has signed a partnership deal with Daiichi Sankyo, giving the drugmaker rights to develop its regenerative heart treatment for the Japanese market.”
If you like this story, please see our blog titled “Cool Tool – Producing 3D Tissue Models of the Airway Epithelium with PneumaCult™”
“The Obama administration on Friday will announce the latest in its scientific “moonshots,” this one in the red-hot field of microbiomes — the trillions of micro-organisms in places like soil and the human gut.”
If you like this story, please see our blog titled “Cool Tools – BrainPhys™: A New Way to Culture Neurons”
“Intarcia Therapeutics Inc.’s big push toward a diabetes treatment approval will mean more work for the company’s Hayward manufacturing site. The company, which moved its headquarters from Hayward to Boston in 2012, reported positive results of the last and biggest of four late-stage trials of its drug-and-device combination to treat type 2 diabetes. That clears the way for the company to submit an application for Food and Drug Administration approval in the fall.”
If you like this story, please see our blog titled “Enabling High Density Cell Banking using a Single-Use, Closed-System”
